Severe facial clefting in Insig-deficient mouse embryos caused by sterol accumulation and reversed by lovastatin

Journal of Clinical Investigation

Volumn 116, Issue 9, 2006, Pages 2356-2365

  Engelking, Luke J ^a   Evers, Bret M ^a   Richardson, James A ^a   Goldstein, Joseph L ^a   Brown, Michael S ^a   Liang, Guosheng ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PROTEIN INSIG 1; PROTEIN INSIG 2; REGULATOR PROTEIN; STEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLEFT FACE; CLEFT PALATE; CONTROLLED STUDY; EAR MALFORMATION; EMBRYO; ENZYME DEGRADATION; GENE MUTATION; HOMOZYGOSITY; LETHARGY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SKELETON; STEROL SYNTHESIS;

ANIMALS; BONE AND BONES; FEMALE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MOUTH ABNORMALITIES; PREGNANCY; STEROLS;

EID: 33748297599     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI28988     Document Type: Article

References (48)

1. Kelley, R.I., and Herman, G.E. 2001. Inborn errors of sterol biosynthesis. Annu. Rev. Genomics Hum. Genet. 2:299-341.
2. Nwokoro, N.A., Wassif, C.A., and Porter, F.D. 2001. Genetic disorders of cholesterol biosynthesis in mice and humans. Mol. Genet. Metab. 74:105-119.
3. Porter, F.D. 2003. Human malformation syndromes due to inborn errors of cholesterol synthesis. Curr. Opin. Pediatr. 15:607-613.
4. Herman, G.E. 2003. Disorders of cholesterol biosynthesis: prototypic metabolic malformation syndromes. Hum. Mol. Genet. 12:R75-R88.
5. Liu, X.Y., et al. 1999. The gene mutated in bare patches and striated mice encodes a novel 3β-hydroxysteroid dehydrogenase. Nat. Genet. 22:182-187.
6. 7 sterol isomerase in the tattered mouse and X-linked dominant chondrodysplasia punctata. Nat. Genet. 22:286-290.
7. Krakowiak, P.A., et al. 2003. Lathosterolosis: an inborn error of human and murine cholesterol synthesis due to lathosterol 5-desaturase deficiency. Hum. Mol. Genet. 12:1631-1641.
8. Fitzky, B.U., et al. 2001. 7-Dehydrocholesterol-dependent proteolysis of HMG-CoA reductase suppresses sterol biosynthesis in a mouse model of Smith-Lemli-Opitz/RSH syndrome. J. Clin. Invest. 108:905-915. doi:10.1172/JCI200112103.
9. Wassif, C.A., et al. 2001. Biochemical, phenotypic and neurophysiological characterization of a genetic mouse model of RSH/Smith-Lemli-Opitz syndrome. Hum. Mol. Genet. 10:555-564.
10. Wechsler, A., et al. 2003. Generation of viable cholesterol-free mice. Science. 302:2087.
11. Irons, M., Elias, E.R., Salen, G., Tint, G.S., and Batta, A.K. 1993. Defective cholesterol biosynthesis in Smith-Lemli-Opitz syndrome. Lancet. 341:1414.
12. Tint, G.S., et al. 1995. Markedly increased tissue concentrations of 7-dehydrocholesterol combined with low levels of cholesterol are characteristic of the Smith-Lemli-Opitz syndrome. J. Lipid Res. 36:89-95.
13. Porter, F.D. 2000. RSH/Smith-Lemli-Opitz syndrome: a multiple congenital anomaly/mental retardation syndrome due to an inborn error of cholesterol biosynthesis. Mol. Genet. Metab. 71:163-174.
14. Opitz, J.M. 1999. RSH (so-called Smith-Lemli-Opitz) syndrome. Curr. Opin. Pediatr. 11:353-362.
15. Kelley, R.I., and Hennekam, R.C.M. 2000. The Smith-Lemli-Opitz syndrome. J. Med. Genet. 37:321-335.
16. Elias, E.R., Irons, M.B., Hurley, A.D., Tint, G.S., and Salen, G. 1997. Clinical effects of cholesterol supplementation in six patients with the Smith-Lemli-Opitz syndrome (SLOS). Am. J. Med. Genet. 68:305-310.
17. Irons, M., et al. 1997. Treatment of Smith-Lemli-Opitz syndrome: results of a multicenter trial. Am. J. Med. Genet. 68:311-314.
18. Starck, L., Lovgren-Sandblom, A., and Bjorkhem, I. 2002. Cholesterol treatment forever? The first Scandinavian trial of cholesterol supplementation in the cholesterol-synthesis defect Smith-Lemli-Opitz syndrome. J. Intern. Med. 252:314-321.
19. Merkens, L.S., et al. 2004. Effects of dietary cholesterol on plasma lipoproteins in Smith-Lemli-Opitz syndrome. Pediatr. Res. 56:726-732.
20. Sikora, D.M., et al. 2004. Cholesterol supplementation does not improve developmental progress in Smith-Lemli-Opitz syndrome. J. Pediatr. 144:783-791.
21. Jira, P.E., et al. 2000. Simvastatin: a new therapeutic approach for Smith-Lemli-Opitz syndrome. J. Lipid Res. 41:1339-1346.
22. Starck, L., Lovgren-Sandblom, A., and Bjorkhem, I. 2002. Simvastatin treatment in the SLO syndrome: a safe approach? Am. J. Med. Genet. 113:183-189.
23. Goldstein, J.L., DeBose-Boyd, R.A., and Brown, M.S. 2006. Protein sensors for membrane sterols. Cell. 124:35-46.
24. Yabe, D., Brown, M.S., and Goldstein, J.L. 2002. Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins. Proc. Natl. Acad. Sci. U. S. A. 99:12753-12758.
25. Yang, T., et al. 2002. Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell. 110:489-500.
26. Horton, J.D., Goldstein, J.L., and Brown, M.S. 2002. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109:1125-1131. doi:10.1172/JCI200215593.
27. Brown, M.S., and Goldstein, J.L. 1997. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 89:331-340.
28. Sever, N., et al. 2003. Insig-dependent ubiquitination and degradation of mammalian 3-hydroxy-3-methylglutaryl-CoA reductase stimulated by sterols and geranylgeraniol. J. Biol. Chem. 278:52479-52490.
29. Sever, N., Yang, T., Brown, M.S., Goldstein, J.L., and DeBose-Boyd, R.A. 2003. Accelerated degradation of HMG CoA reductase mediated by binding of Insig-1 to its sterol-sensing domain. Mol. Cell. 11:25-33.
30. Engelking, L.J., et al. 2005. Schoenheimer effect explained - feedback regulation of cholesterol synthesis in mice mediated by Insig proteins. J. Clin. Invest. 115:2489-2498. doi:10.1172/JCI25614.
31. Ferguson, M.W. 1988. Palate development. Development. 103(Suppl.):41-60.
32. Dietschy, J.M., and Spady, D.K. 1984. Measurement of rates of cholesterol synthesis using tritiated water. J. Lipid Res. 25:1469-1476.
33. Kita, T., Brown, M.S., and Goldstein, J.L. 1980. Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J. Clin. Invest. 66:1094-1100.
34. Le Douarin, N.M., and Kalcheim, C. 1999. The neural crest. Cambridge University Press. Cambridge, United Kingdom. 469 pp.
35. Taya, Y., O'Kane, S., and Ferguson, M.W.J. 1999. Pathogenesis of cleft palate in TGF-β3 knockout mice. Development. 126:3869-3879.
36. Murray, J.C. 2002. Developmental biology: frontiers for clinical genetics. Clin. Genet. 61:248-256.
37. Stanier, P., and Moore, G.E. 2004. Genetics of cleft lip and palate: syndromic genes contribute to the incidence of non-syndromic clefts. Hum. Mol. Genet. 13:R73-R81.
38. Porter, J.A., Young, K.E., and Beachy, P.A. 1996. Cholesterol modification of hedgehog signaling proteins in animal development. Science. 274:255-259.
39. Tabin, C.J., and McMahon, A.P. 1997. Recent advances in Hedgehog signalling. Trends Cell Biol. 7:442-446.
40. Nohturfft, A., Brown, M.S., and Goldstein, J.L. 1998. Sterols regulate processing of carbohydrate chains of wild-type SREBP cleavage-activating protein (SCAP), but not sterol-resistant mutants Y298C or D443N. Proc. Natl. Acad. Sci. U. S. A. 95:12848-12853.
41. Chiang, C., et al. 1996. Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. Nature. 383:407-413.
42. Villavicencio, E.H., Walterhouse, D.O., and Iannaccone, P.M. 2000. The Sonic Hedgehog-Patched-Gli pathway in human development and disease. Am. J. Hum. Genet. 67:1047-1054.
43. Brown, M.S., Faust, J.R., Goldstein, J.L., Kaneko, I., and Endo, A. 1978. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J. Biol. Chem. 253:1121-1128.
44. Xu, F., et al. 2005. Dual roles for cholesterol in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 102:14551-14556.
45. Belknap, W.M., and Dietschy, J.M. 1988. Sterol synthesis and low density lipoprotein clearance in vivo in the pregnant rat, placenta, and fetus. J. Clin. Invest. 82:2077-2085.
46. Shimano, H., et al. 1996. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J. Clin. Invest. 98:1575-1584.
47. Moebius, F.F., Fitzky, B.U., and Glossmann, H. 2000. Genetic defects in postsqualene cholesterol biosynthesis. Trends Endocrinol. Metab. 11:106-114.
48. Abbott, B.D. 2000. Palatal dysmorphogenesis: palate organ culture. In Developmental biology protocols. R.S. Tuan and C.W. Lo, editors. Humana Press Inc. Totowa, New Jersey, USA. 195-201.